[Differential therapy of advanced bladder carcinoma and of postoperative adjuvant chemotherapy (author's transl)].
Advanced bladder carcinoma still has a poor prognosis. While the five-year-survival in stage T1N0M0 is about 80%, less than 50% of the patients in stage T2N0M0 survive 5 years. This prognosis could not be altered by a more radical operation or by radiation therapy. Therefore we started postoperative adjuvant chemotherapy in 1972. First we tested the effect of three different cytostatic drug therapy schedules. Although successful treatment was achieved in several cases, there were other patients who did not respond to one of the three therapy schedules. We then started applying all three schedules, one after the other, in intervals of 4 weeks. Therapeutic procedure now is: After diagnosis by cystoscopy and histology and TNM-classification, urologic therapy is performed (electroresection, cystectomy, etc.). Then in stage T2-4N0-1M0-1 postoperative adjuvant chemotherapy follows. Thus far, we have achieved complete remission in all patients except one (after radiation therapy). No definite comments as to survival can be made at this time.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007083:Iliac Artery; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008727:Methotrexate / Q000008:administration & dosage; D011182:Postoperative Care; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D014747:Vinblastine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Differentialtherapie des fortgeschrittenen Blasenkarzinoms unter Berücksichtigung neuer chemotherapeutischer Aspekte.